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Abstract
Cerebral preconditioning (PC) confers endogenous brain protection after stroke. Ischemic stroke patients with a prior transient
ischemic attack (TIA) may potentially be in a preconditioned state. Although PC has been associated with the activation of pro-
survival signals, the mechanism by which preconditioning confers neuroprotection is not yet fully clarified. Recently, we have
described that PC-mediated neuroprotection against ischemic insult is promoted by p53 destabilization, which is mediated by its
main regulatorMDM2.Moreover, we have previously described that the human Tp53 Arg72Pro single nucleotide polymorphism
(SNP) controls susceptibility to ischemia-induced neuronal apoptosis and governs the functional outcome of patients after stroke.
Here, we studied the contribution of the human Tp53 Arg72Pro SNP on PC-induced neuroprotection after ischemia. Our results
showed that cortical neurons expressing the Pro72-p53 variant exhibited higher PC-mediated neuroprotection as compared with
Arg72-p53 neurons. PC prevented ischemia-induced nuclear and cytosolic p53 stabilization in Pro72-p53 neurons. However, PC
failed to prevent mitochondrial p53 stabilization, which occurs in Arg72-p53 neurons after ischemia. Furthermore, PC promoted
neuroprotection against ischemia by controlling the p53/active caspase-3 pathway in Pro72-p53, but not in Arg72-p53 neurons.
Finally, we found that good prognosis associated to TIA within 1 month prior to ischemic stroke was restricted to patients
harboring the Pro72 allele. Our findings demonstrate that the Tp53 Arg72Pro SNP controls PC-promoted neuroprotection against
a subsequent ischemic insult bymodulatingmitochondrial p53 stabilization and then modulates TIA-induced ischemic tolerance.
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Introduction
The restriction in blood supply to the brain causes a shortage
of oxygen and glucose to maintain cellular metabolism,
which elicits a pathological response. Paradoxically, tran-
sient brief episodes of controlled ischemia confer protection
against a subsequent prolonged ischemia. This phenome-
non described as cerebral preconditioning (PC) has been
evidenced both in vitro and in vivo models [1–3]. The effi-
cacy of PC in reducing brain injury after an ischemic dam-
age has also been demonstrated in clinical studies. Transient
ischemic attack (TIA) is considered to be the clinical corre-
late of PC. Thus, patients with previous ipsilateral TIA be-
fore an ischemic stroke had better outcome than patients
without previous TIA [4–6]. Therefore, it provides clear
evidence that PC may be effective to reduce brain injury in
human against ischemic insult [7–10].
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In recent years, there has been increasing interest in the
study of molecular mechanisms responsible for PC-
mediated neuroprotection, as well as its possible applica-
tion in therapies for cerebral ischemic damage [1, 2]. It
was reported that cerebral PC is implicated in different
mechanisms such as the inhibition of glutamate release
[11, 12], or the increase in neuronal resistance to the
excitotoxic insult [13–15]. This neuroprotective response
initiated through the post-translational modification of
proteins is rapid and occurs within minutes to hours
[16–18]. However, the molecular mechanisms responsible
for PC-mediated neuroprotection have not been elucidated
so far.
The deletion of the Tp53 gene is associated with neuro-
protection following ischemia [19].Moreover, since nuclear
p53 transcriptional activity has been associated specifically
with apoptosis of cortical neurons [20], the interference with
p53 activity has inspired potential applications in therapy.
The protein p53 is translocated from the cytosol to the mi-
tochondria and mediates transcriptional dependent or inde-
pendent apoptosis cell death [21, 22], in response to stimulus
such as ischemia [20]. In this context, several studies have
shown that p53 is translocated from the cytosol to the mito-
chondria [23, 24] in response to ischemia. Indeed, p53 me-
diates apoptosis through its direct action in the mitochon-
dria, where p53 binds to pro-apoptotic PUMA and Bax, pro-
moting cytochrome c release [25], in different cell types and
tissues, including brain [22, 26]. In contrast, the inhibition of
caspase-3-mediated apoptotic pathway activation by PC has
also been associated with ischemic tolerance in transient
cerebral ischemia in vivo models [27]. Accordingly, several
studies have shown that PC decreases neuronal apoptosis
and reduces the subsequent neurological deficits and infarct
volume within 24 to 72 h after ischemia [28, 29], by promot-
ing ischemic tolerance [27]. In a recent work, we have dem-
onstrated that PC confers neuronal ischemic tolerance by
increasingMDM2 protein level, which promotes its interac-
tion with p53 and triggers p53 nuclear and cytosolic desta-
bilization [30]. Indeed, our previous results have demon-
strated that PC attenuates ischemia-induced activation of
the p53/PUMA/caspase-3 signaling pathway and subse-
quent neuronal death. Hence, the aim of our study was to
identify the function of p53 and related proteins on neuro-
protection associated to PC prior to a later ischemic insult
and its role in neuronal ischemic tolerance.
Previously, we have identified that the human Tp53
Arg72Pro polymorphism explains different functional
prognosis in stroke [22, 31]. We found that Arg72-p53,
but not Pro72-p53 polymorphic variant, interacts directly
with Bcl-xL in the mitochondria, which increases neuronal
vulnerability to ischemia-induced apoptotic cell death [22].
In addition, our group have recently published that the
Tp53 Arg72Pro SNP determines neovascularization, brain
repair, and neurological recovery after intracerebral hemor-
rhage [31]. Here, we study the function of human Tp53
Arg72Pro SNP on PC-induced neuroprotection and ische-
mic tolerance. Our results show that PC prevented
ischemia-induced nuclear and cytosolic p53 stabilization
in Pro72-p53; however, this effect was not observed in
Arg72-p53, cortical neurons. Moreover, PC prevented
ischemia-induced neuronal apoptosis and caspase-3 activa-
tion, leading to ischemic tolerance in Pro72-p53 cortical
neurons. Hence, here, we aim to report for the first time
that the Tp53 Arg72Pro SNP modulates PC-induced neu-
roprotection against ischemia by controlling the p53/
caspase-3 signaling pathway. Moreover, we aim to confirm
the relevance of the Tp53 Arg72Pro SNP in functional out-
come of ischemic stroke patients within the first month
after a transitory ischemic attack (TIA).
Methods
Primary Cultures of Cortical Neurons Neuronal cultures were
prepared from E14.5 mouse embryo cortices. The humanized
knock-in mice for the Tp53 Arg72Pro SNP were kindly donat-
ed by Prof D.G. Johnson (The University of Texas MD
Anderson Cancer Center, Smithville, Texas, USA) [32].
Animals were maintained in specific-pathogen-free facilities
at the University of Salamanca, in accordance with Spanish
legislation (RD53/2013) under license from the Spanish gov-
ernment and the EU (2010/63/EU). Protocols were approved
by the Bioethics Committee of the University of Salamanca.
Neurons expressing two different polymorphic variants
(Pro72-p53 neurons or Arg72-p53 neurons) were seeded at
1.8 × 105 cells/cm2 in Neurobasal medium (Invitrogen,
Madrid, Spain) supplemented with 2% B27 (Invitrogen) and
glutamine 2 mM (Invitrogen), and incubated at 37 °C in a
humidified 5%CO2-containing atmosphere. Half of the culture
medium was replaced with fresh medium every 3–4 days.
Oxygen Glucose Deprivation and Preconditioning Models
After 9–10 DIV, neurons were exposed to oxygen and glucose
deprivation (OGD) induced by incubating cells at 37 °C for
90 min in an incubator equipped with an air lock and contin-
uously gassed with 95% N2/5% CO2 (Thermo Scientific
Forma Water Jacket CO2 incubator); with a CO2 infrared sen-
sor and variable oxygen control, connecting with injection of
N2 gas supply to control oxygen at suppressed levels and a
fuel cell as oxygen control sensor that puts out a linear milli-
volt signal based on O2 content of the chamber and provides
fast recovery to desired hypoxic conditions for reliable and
accurate control. The incubation medium (buffered Hanks’
solution without glucose: 5.26 mM KCl, 0.43 mM KH2PO4,
132.4 mM NaCl, 4.09 mM NaHCO3, 0.33 mM Na2HPO4,
2 mM CaCl2, and 20 mM HEPES, pH 7.4) was previously
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gassed with 95% N2/5% CO2 for 30 min. Under these condi-
tions, oxygen concentrations in the incubation medium were
6.7 ± 0.5 μM as measured with a Clark-type oxygen electrode
[33, 34]. In case of preconditioning (PC), the neurons were
treated with a moderated subtoxic concentration of N-Methyl-
D-Aspartate (20 μM,NMDA-PC) for 2 h prior to a subsequent
lethal ischemia induced by oxygen and glucose deprivation
(OGD; 90 min); (NMDA-PC + OGD) previously validated
PC method [30, 35, 36]. In parallel, neurons were incubated
under Normoxia (Nx) or NMDA-PC conditions at 37 °C in a
humidified atmosphere of 95% air/5% CO2 in buffered
Hanks’ solution buffer. Under these conditions, oxygen con-
centrations in the incubation medium were 190 ± 15 μM as
measured with a Clark-type oxygen electrode. Unless other-
wise stated, neuronal samples were collected at 4 h of reoxy-
genation after OGD and processed accordingly.
Flow Cytometric Detection of Apoptotic Cell Death Neurons
were carefully detached from the plates using 1 mM EDTA
(tetrasodium salt) in PBS (pH 7.4) at room temperature.
Cells were stained with annexin V-APC and 7-AAD in bind-
ing buffer (100 mM HEPES, 140 mM NaCl, 2.5 mM
CaCl2), according to the manufacturer’s instructions and
performed exactly as we previously described [22], to de-
termine quantitatively the percentage of apoptotic neurons
by flow cytometry. Four replicates per condition (3 × 105
cells each) were analyzed on a FACScalibur flow cytometer
(15 mW argon ion laser tuned at 488 nm; CellQuest soft-
ware, BD Biosciences). The annexin V-APC stained cells
that were 7AAD negative were considered to be apoptotic
(AnnexinV+/7AAD−).
Flow Cytometric Analysis of Membrane Potential (Ψm) Ψm
was assessed using the MitoProbe DilC1(5) Assay Kit for
Flow Cytometry (Invitrogen), and stained cells were analyzed
on the FL1 and FL4 channels of a FACScalibur flow
cytometer (15 mW argon ion laser tuned at 488 nm;
CellQuest software; BD Biosciences) as we previously de-
scribed [22]. Ψm values were expressed as percentages, and
the 10 μM of mitochondrial uncoupler carbonyl cyanide
4-(trifluoromethoxy) phenylhydrazone (10 μM; FCCP) was
used for 15 min to define the 0% Ψm values.
Quantitative Reverse Transcription-Polymerase Chain
Reaction (RT-qPCR) Analysis Total RNA samples were purified
from neurons using a commercially available kit (Sigma) and
RT-qPCR was performed with Power SYBR Green RNA-to-
CT TM 1-Step kit (Applied Biosystems, Township, USA).
Reverse transcription was performed for 30 min at 48 °C, and
PCR conditions were 10 min at 95 °C followed by 40 cycles of
15 s at 95 °C plus 1 min at 55 °C using the following forward
and reserve primers, respectively (Thermo Scientific,
Offenbach, Germany), 5′-ATTCTGCCCACCACACAGCG
ACA-3′ and 5′ AGGGCTTCCTCTGGGCCTTCTA-3′ (p53),
5′-GGGTGTGAACCACGAGAAAT-3′ and 5′-GACT
GTGGTCATGAGCCCTT-3′ (Gapdh). The mRNA abundance
of each transcript was normalized to the Gapdh mRNA abun-
dance obtained in the same sample. The relative mRNA levels
were calculated using theΔΔCt method and were expressed as
the fold change between sample and calibrator.
Caspase-3 Activity Assay Caspase-3 activity was assessed in
cell lysates and according to manufacturers’ instructions via
Fluorimetric Assay kit CASP3F from SIGMA and read at
emission wavelength 405 nm. The method is based on the
release of the fluorescent 7-amino-4-methylcoumarin
(AMC) moiety. The AMC concentration is calculated using
a AMC standard.
Western BlottingNeurons were lysed in buffer containing 1%
SDS, 2 mM EDTA, 150 mM NaCl, 12.5 mM Na2HPO4, and
1% Triton X-100 (NP40: 1% NP40, EDTA diK+ 5 mM, Tris
pH 8 20 mM, NaCl 135 mM, and 10% glycerol), supplement-
ed with phosphatase inhibitors (1 mM Na3VO4 and 50 mM
NaF) and protease inhibitors (100 μM phenylmethylsulfonyl
fluoride, 50 μg/ml anti-papain, 50 μg/ml pepstatin, 50 μg/ml
amastatin, 50 μg/ml leupeptin, 50 μg/ml bestatin, and
50 μg/ml soybean trypsin inhibitor), stored on ice for
30 min, and boiled for 5 min. Protein concentrations were
determined with the BCA (bicinchoninic acid) method, using
bovine serum albumin as a standard (BCA Protein Assay kit,
Thermo Fisher Scientific). Extracts were centrifuged at
13,000g for 5 min at 4 °C. Aliquots of lysed, nuclear, cytosol-
ic, or mitochondrial extracts (20–70 μg protein) were subject-
ed to SDS-polyacrylamide gel (Mini PROTEAN; Bio-Rad
Laboratories) and blotted with anti-p53 (1:100) (554157,
BDBiosciences), anti-cleaved caspase-3 (Asp175, 9661, Cell
Signaling), anti-MDM2 (2A10, ab16895), anti-PUMA
(ab54288) (Abcam, Cambridge, UK), and anti-lamin B (sc-
374015, Santa Cruz Biotechnology, Heidelberg, Germany)
anti-GAPDH (Ambion, Cambridge, UK) overnight at 4 °C.
Signal detection was performed with an enhanced chemilumi-
nescence detection kit (Thermo Fisher Scientific), and the au-
toradiograms were scanned. Band intensities were quantified
using ImageJ software [37].
Subcellular Fractionation Cells were washed with cold PBS
containing 1 mM MgCl2, harvested with cytosolic buffer
(10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 1 mM
EDTA, 0.1% NP-40, v/v, 1.5 M sucrose, and protease and
phosphatase inhibitors mixture, pH 7.9), triturated with a mi-
cropipette to promote cell lysis, left on ice for 30 min, and
vortexed for 10 s. After checking cell lysis under a light mi-
croscope, extracts were centrifuged at 830×g for 10min. Lysis
of the nuclei was performed by resuspending the nuclear pellet
in nuclear buffer (50 mM HEPES, 1.5 mM MgCl2, 10 mM
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KCl mM, 0.5 mM NaCl, 1 mM EDTA, 1% NP-40, v/v, and
protease and phosphatase inhibitor mixture, pH 7.9), triturated
with a micropipette, left on ice for 2 h, vortexed (10 s), boiled
(5 min), and sonicated (5 min). The supernatant (mitochondri-
al and cytosolic fractions) was then centrifuged at 17,000×g
for 12 min (4 °C), and the cytosolic fraction (supernatant) was
lysed in 2× RIPA buffer (2% sodium dodecyl sulfate, 2 mM
EDTA, 2 mMEGTA, and 50mMTris, pH 7.5), supplemented
with phosphatase inhibitors (1 mMNa3VO4 and 50 mMNaF)
and protease inhibitors (100 μM phenylmethylsulfonyl fluo-
ride (PMSF), 50 μg/ml anti-papain, 50 μg/ml pepstatin,
50 μg/ml amastatin, 50 μg/ml leupeptin, 50 μg/ml bestatin,
and 50 μg/ml soybean trypsin inhibitor), and boiled for 5 min
[37]. The mitochondrial fraction (pellet) was resuspended in
isolation medium (320 mM sucrose, 1 mM potassium EDTA,
and 10 mM Tris-HCl, pH 7.4) and was homogenized in a
tight-fitting glass—Teflon homogenizer (20 strokes) [22,
38]. Mitochondrial fraction was lysed with 2× RIPA buffer
for protein analysis by immunoblotting.
Immunocytochemistry Neurons grown on glass coverslips
were fixed with 4% (v/v, in PBS) paraformaldehyde for
30 min and immunostained with rabbit anti-cleaved caspase3
(Asp175) (1:300; Cell Signaling Techn, Inc.), mouse anti-
MAP2 (1:500; SIGMA) [39], mouse anti-p53 (1:200;
554157, BD Biosciences) [30], and rabbit-COX IV (1:1000;
ab16056, Abcam) antibodies. Immunolabeling was detected
using anti-rabbit IgG–Cy3 (1:500) or anti-mouse IgG–Cy2
(1:500; Jackson ImmunoResearch). Coverslips were washed,
mounted in SlowFade light anti-fade reagent (Invitrogen) on
glass slides, and examined using a microscope (Nikon Inverted
microscope Eclipse Ti-E) equipped with × 20 objective and a
pre-centered fiber illuminator Nikon Intensilight C-HGFI and
black and white charge-coupled device digital camera
Hamamatsu ORCAER, or on a scanning laser confocal micro-
scope (BSpinning disk^ Roper Scientific Olympus IX81) with
three lasers (405, 491, and 561 nm) and equipped with × 40
and × 63 PL Apo oil-immersion objective for high resolution
imaging and device digital camera Evolve Photometrics.
Patient Cohorts Nested case control study was designed on
previously collected cohorts of patients with ischemic stroke
defined as infarction of the central nervous system tissue [40],
between 2012 and 2015 in three University Hospitals
(Salamanca, Valladolid, and Lleida, Spain). Among this co-
hort, we selected patients with prior TIA defined as a brief
episode of neurological dysfunction caused by focal brain or
retinal ischemia, with clinical symptoms typically lasting less
than 1 h, and without evidence of acute infarction [40] and a
randomized subset of patients without it. Inclusion criteria
were acute ischemic stroke patients, previously independent
for daily life activities, with a TIAwithin 1 month before the
stroke, and patients without it. Patients were admitted within
the first 24 h after the onset of symptoms, or from the start of
sleep in those with symptoms upon awakening. Exclusion
criteria were intracerebral hemorrhage, TIA history more than
1 month before the stroke, insufficient clinical data, and lack
of informed consent. Eighty-five patients fulfilled all inclusion
criteria for the study. Clinical and epidemiological data were
taken from patients’ charts. The study was approved by the
local ethics committees. All the patients or their relatives pro-
vided their informed consent before taking part of the study.
Clinical Variables Patients were admitted to the Neurology
departments and treated according to the Guidelines of the
cerebrovascular disease study Group of the Spanish Society
of Neurology [41]. Baseline demographic and clinical data
included age, sex, pre-onset modified Rankin Scale (mRS),
past medical history, vascular risk factors, and previous treat-
ment. Standard 12-lead ECG and cranial Computed
Tomography (CT) or brain Magnetic Resonance (MR) were
performed at admission. Details of previous TIAwere obtain-
ed from the patient and medical records. Standard definitions
of TIA and stroke were used. Stroke subtypes were classified
according to the TOAST criteria [42]. Stroke severity was
assessed using the National Institute of Health Stroke Scale
(NIHSS) at admission. Functional outcome was evaluated at
3 months after stroke using the mRS. NIHSS and mRS were
evaluated by internationally certified neurologists. The main
outcome measure for all patients was functional status at
3 months; mRS score ≤ 2 was considered good outcome [43].
Human Tp53 Polymorphism Analysis Genotyping of human
Tp53 polymorphism was performed at the University of
Salamanca by authors blinded to the clinical status of patients,
by using the PCR-RFLP technique [22]. The Tp53 SNP of
exon 4 at codon 72 (Arg72Pro; rs1042522) was detected by
amplifying genomic DNA with the forward primer 5′-TCTA
CAGTCCCCCTTGCCGT-3′ and the reverse primer 5′-
CTGACCGTGCAAGTCACAGA-3′. Tp53 exon 4, where
BstU1 (Bsh1236I) RFLP is located, was amplified within a
298-bp DNA fragment. Digests were separated on agarose gel
(3%) and the Midori Green Advance-stained DNA fragments
(Nippon Genetics Europe GmbH, Düren, Germany) were an-
alyzed under a UV source using the Bio-Rad Universal Hood
II Gel Imager system (Bio-Rad, CA, USA). The distribution
of genotype frequencies in Arg72Pro between the stroke pa-
tients was within the Hardy–Weinberg equilibrium (p > 0.1 in
all cases). As the Pro allele is likely to exert a dominant effect
on the Arg one [22], two groups were considered for this
study: Pro (Pro/Pro and Pro/Arg genotypes) and Arg (Arg/
Arg genotype) patients.
Statistical Analysis The results obtained in cell cultures are
expressed as means ± SEM values from four different culture
preparations. Statistical analyses were performed by one-way
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analysis of variance, followed by the least significant differ-
ence multiple range test. In these cases, p < 0.05 value was
considered significant. Clinical results are expressed as per-
centages for categorical variables. For the continuous vari-
ables, the results are expressed as either the mean ± S.D. or
median (25th and 75th percentiles) depending on whether or
not the data followed a normal distribution, respectively. The
Kolmogorov–Smirnov test was used for testing the normality
of the distribution. The Student t test (normal data) or the
Mann–Whitney test (non-normal data) was used to compare
continuous variables between two groups. Proportions were
compared using the x2 and fisher test. In all instance, p < 0.05
values were considered significant. Statistical analyses were
performed using SPSS Statistics 22.0 for Macintosh (IBM,
Madrid, Spain).
Results
NMDA-PC Prevents Ischemia-Induced p53
Stabilization in Pro72-p53 Neurons, but Not
in Arg72-p53 Neurons
We have previously identified that the Arg72-p53, but not
Pro72-p53, interacts directly with anti-apoptotic mitochondri-
al Bcl-xL, then increasing vulnerability to ischemia-induced
apoptotic death in cortical neurons [22]. To study the role of
human Tp53 Arg72Pro SNP on the PC-mediated neuroprotec-
tion, we obtained cortical neurons from humanized Tp53
knock-in mice for the Arg72Pro SNP. First, neurons express-
ing human Pro72-p53 or Arg72-p53 variants were exposed to
a validated in vitro model of PC induced by NMDA (NMDA-
PC) [30, 36] and/or oxygen glucose deprivation (OGD) pro-
tocol [33]. As shown in Fig. 1a, b, 4 h of reoxygenation fol-
lowing OGD induced p53 stabilization and the expression of
its transcriptional target PUMA in both Pro72-p53 and Arg72-
p53 neurons, when compared with normoxic (Nx) conditions.
These results demonstrate that neurons expressing either
Pro72-p53 or Arg72-p53 are equally sensitive to ischemia-
mediated p53 stabilization. However, NMDA-PC prior to
the insult (OGD) prevented p53 stabilization in Pro72-p53
neurons, but not in neurons expressing the Arg72-p53 SNP
variant (Fig. 1a, b). Since NMDA-PC increasedMDM2 levels
in neurons (Fig. 1a) and this effect was maintained after OGD
in both genotypes, we therefore confirmed that only
preconditioned Pro72-p53 neurons might display p53 destabi-
lization after ischemia through a MDM2-dependent mecha-
nism. According to our previous results [30], we also verified
that p53 mRNA remained unaltered during preconditioning
(Fig. 1c), which highlights the importance of post-
translational regulation of p53 after ischemic events. These
results demonstrate that human Tp53 Arg72Pro polymor-
phism conditions NMDA-PC-mediated p53 destabilization
after OGD, which might control neuronal susceptibility to
the ischemic insult.
To transactivate p53 target genes such as p21, PUMA, and
p53 itself, the stabilization and subsequent nuclear transloca-
tion of p53 is required [44, 45]. Thus, we investigated whether
NMDA-PC prevents ischemia-induced p53 nuclear transloca-
tion. Nuclear, cytosolic and mitochondrial neuronal fractions
were obtained separately, and protein levels were analyzed by
Western blotting. As shown in Fig. 2a, p53 is translocated to
the nucleus in both Pro72-p53 and Arg72-p53 neurons after
reoxygenation following ischemia. However, the nuclear (Fig.
2a) and cytosolic (Fig. 2b) destabilization of p53 induced by
NMDA-PC was evidenced only in Pro72-p53 neurons at 4 h
after OGD. In the case of Arg72-p53 neurons, NMDA-PC
failed to prevent ischemia-induced mitochondrial p53 accu-
mulation, as shown after Western blot analysis (Fig. 2c) and
co-immunostaining with anti-p53 and mitochondrial marker
(Fig. 2d), respectively. Moreover, preconditioned neurons ex-
pressing Pro72-p53 showed intact mitochondrial membrane
potential (Δψm) in contrast to those expressing Arg72-p53,
which collapsed their Δψm (Fig. 2e). Hence, Arg72-p53 cor-
tical neurons are more susceptible to p53-associated mito-
chondria dysfunction than Pro72-p53 neurons, as we previ-
ously described [22]. Moreover, NMDA-PC failed to prevent
p53 stabilization after ischemia in neurons expressing the
Arg72-p53 variant.
NMDA-PC Prevents Ischemia-Induced Apoptosis
and Caspase-3 Activation in Pro72-p53 Neurons,
but Not in Arg72-p53 Neurons
The transcriptional enhancement of pro-apoptotic genes me-
diated by p53, such as PUMA [44, 45], contributes to activa-
tion of caspases and subsequent neuronal death [46]. Having
demonstrated that the Tp53 Arg72Pro polymorphism controls
p53 stabilization after PC, we next studied its relevance in
NMDA-PC-induced neuroprotection. Then, we measured ap-
optotic cell death (Fig. 3a, b) and caspase-3 activation (Fig.
3c) in neurons expressing either Pro72-p53 or Arg72-p53
polymorphic variants. According to our previous results
[22], flow cytometry analysis revealed that reoxygenation fol-
lowing OGD promoted apoptosis in a time-dependent manner
(Fig. 3a). We also observed that NMDA-PC prevented the
ischemia-induced apoptosis in Pro72-p53, after 4 h of reoxy-
genation (Fig. 3b), which confirmed the neuroprotective effect
of controlled NMDA-PC in cortical neurons subjected to is-
chemia. However, NMDA-PC-induced neuroprotection was
not observed in Arg72-p53 neurons. Additionally, OGD in-
duced caspase-3 activation in both genotypes as revealed by
fluorimetry assay, which was exclusively prevented by
NMDA-PC in Pro72-p53 neurons (Fig. 3c). Furthermore,
co-immunostaining with anti-MAP2 (neuronal marker) and
anti-active caspase-3 antibodies confirmed the activation of
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caspase-3 in neurons after OGD, as well as the lower activa-
tion of caspase-3 in preconditioned Pro72-p53 neurons, when
compared to Arg72-p53 ones after the ischemic insult (Fig.
3d, e). These results validated the PC method utilized and
demonstrated the effectiveness of NMDA-PC-promoted con-
trol of p53/Caspase-3 pathway in Pro72-p53 neurons, but not
in Arg72-p53 neurons.
TIA Prevents Poor Prognosis After Stroke in Patients
with the Pro72 allele, but Not in Those
with the Arg/Arg Genotype
Finally, to study the possible clinical relevance of our results,
we assessed whether the Tp53 Arg72Pro SNP was associated
with TIA-induced good prognosis after ischemic stroke. We
used a cohort of patients with or without TIAwithin 1 month
prior stroke and were matched by functional outcome based
on the mRS score [43] (see Table 1 for baseline characteris-
tics). First, we confirm in our cohort that patients suffering a
TIA before stroke presented better prognosis at 3 months than
patients without previous TIA (Fig. 4a). Next, we study the
effects of a TIAwithin a month prior stroke according to Tp53
Arg72Pro patients’ genotype. We found that significant TIA-
induced reduction in median mRS scores at 3 months after
stroke was observed in patients harboring the dominant Pro
allele (referred as Pro patients, Fig. 4b), when compared with
those not suffering a previous TIA (No TIA) (Fig. 4b).
However, this effect was not so evident in patients homozy-
gous Arg/Arg (referred as Arg patients, Fig. 4c). Moreover,
even though TIA also influence the functional outcome of
preconditioned Arg patients, 33% of Arg patients exhibited
poor prognosis (mRS > 2) after stroke; whereas, the entire
group of Pro patients with previous TIA had a favorable out-
come (mRS ≤ 2) at 3 months after ischemia stroke (Table 2),
suggesting that the Arg72Pro SNP modulates the effective-
ness of the protective effect exerted by TIA against a subse-
quent ischemic insult.
Discussion
Several studies have revealed that polymorphic variants in
genes encoding apoptotic proteins could be highly valuable
in the diagnosis of stroke [47] and that p53 stabilization
Fig. 1 NMDA-PC promotes p53 destabilization in Pro72-p53 neurons.
Cortical neurons (9–10DIV) obtained from humanized knock-in mice for
the both codon Arg72Pro variants of p53 (Pro72-p53 and Arg72-p53)
were treated with a moderate subtoxic N-Methyl-D-Aspartate (20 μM)
for 2 h prior to OGD (NMDA-PC+OGD), a validated in vitro model of
PC and p53 and its related protein expression, (a) neuronal extracts were
analyzed by Western blotting and (b) relative protein abundance of p53
was quantified. (a, b) OGD induced p53 stabilization and its target
PUMA at 4 h after OGD, which was prevented by NMDA-PC only in
Pro72-p53 neurons, as revealed by Western blotting. Furthermore, as
shown in (a) similar expression levels of its E3 ubiquitin ligase, MDM2
were found in neurons expressing both Arg72Pro variants of p53, after
OGD and NMDA-PC conditions. GADPH protein levels were used as
loading control. A representative Western blot is shown out of four. (c)
RT-qPCR analysis of p53 gene reveals that p53 mRNA remained
unaltered after OGD in neurons expressing for both Arg72Pro variants
of p53. Data are means ± S.E.M. (n = 4 independent neuronal cultures).
Statistical analysis of the results was evaluated by one-way analysis of
variance, followed by the least significant difference multiple range test.
Student’s t test was used for comparisons between two groups of values.
In all cases, p < 0.05 value was considered significant.*p < 0.05 versus
Nx. #p < 0.05 versus OGD
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contributes to ischemia-induced neuronal apoptosis [19, 48].
Moreover, we recently found that Tp53 Arg72Pro SNP
controls susceptibility to apoptosis after ischemia and dictates
the prognosis of stroke patients [22, 31]. Here, we described
Fig. 2 NMDA-PC failed to prevent mitochondrial p53 destabilization in
Arg72-p53 neurons. Cortical neurons from mice expressing human
Pro72-p53 or Arg72-p53 variant (9–10 DIV) were exposed to a
validated in vitro model of PC. NMDA-PC promoted p53
destabilization levels at 4 h after OGD, only in Pro72-p53 neurons.
This effect occurred in both nuclei (a) and cytosol (b), which confirmed
that NMDA-PC prevented the accumulation of p53 induced by OGD
only in Pro72-p53 neurons. Lamin B and GAPDH protein levels were
used as nuclear and cytosolic loading control, respectively. (c) OGD
induced mitochondria p53 stabilization in Arg72-p53 neurons but not in
Pro72-p53 neurons, as assayed by Western blotting analysis. HSP60
protein levels were used as loading control. A representative Western
blot is shown out of four. (d) This effect was corroborated after co-
immunostaining for anti-p53 (red) and mitochondrial marker anti-COX
IV (green). Scale bar 20μm. (e) OGD decreasedmitochondria membrane
potential (Ψm) by 18% in Pro72-p53 neurons and 50% in Arg72-p53
neurons. Nevertheless, NMDA-PC prevented OGD-induced
mitochondria membrane potential decreased in Pro72-p53 neurons, but
not in Arg72-p53 neurons, at 4 h after OGD. Data are means ± S.E.M.
Statistical analysis of the results was evaluated by one-way analysis of
variance, followed by the least significant difference multiple range test.
Student’s t test was used for comparisons between two groups of values.
In all cases, p < 0.05 value was considered significant. In all cases, *p <
0.05 versus Nx and #p < 0.05 versus OGD
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for the first time that the human Tp53 Arg72Pro SNP has a
key function in NMDA-PC-induced neuroprotection and
modulates neuronal ischemic tolerance against ischemia-
induced apoptosis.
Fig. 3 NMDA-PC prevents ischemia-induced apoptosis and promoted
caspase-3 activation in Pro72-p53 neurons. Cortical neurons from mice
expressing human Pro72-p53 or Arg72-p53 polymorphic variants (9–
10 DIV) were exposed to a validated in vitro model of PC. (a) At 4 h
after OGD time-dependently induced neuronal apoptosis in neurons
expressing both human Arg72Pro polymorphism variants of p53
(Pro72-p53 or Arg72-p53 neurons), as revealed by flow cytometry. (b)
This effect was prevented byNMDA-PC in Pro72-p53 neurons, but not in
Arg72-p53 neurons. The percentage of annexin V-APC stained neurons
that were 7AAD negative were considered to be apoptotic (AnnexinV+/
7AAD−). Accordingly, NMDA-PC also prevented the activation of
caspase-3 induced by OGD, as revealed by both fluorimetry assay (c)
and immunostaining (d and e) at 4 h after OGD. These results validates
the PC method utilized and confirm that preconditioned Pro72-p53
neurons displayed neuroprotection against ischemia. (d) Fluorescence
microphotographs of both Pro72-p53 and Arg72-p53 neurons were
exposed under four conditions Nx, NMDA-PC, OGD, NMDA-PC+
OGD (d) or under NMDA-PC+OGD (e), described previously and after
immunostaining for activate caspase-3 (red), MAP-2 (green). Scale bar:
50 μm (d) and 25 μm (e). Data are means ± S.E.M. (n = 3 independent
neuronal cultures). Statistical analysis of the results was evaluated by one-
way analysis of variance, followed by the least significant difference
multiple range test. Student’s t test was used for comparisons between
two groups of values. In all cases, p < 0.05 was considered significant. In
all cases *p < 0.05 versus Nx (data not shown in a), and #p < 0.05 versus
OGD
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The similar stabilization of p53 reported in Pro72-p53
and Arg72-p53 neurons after OGD, along with unaltered
levels of p53 mRNA in ischemic neurons confirms the
implication of post-translational mechanism in the
ischemia-induced stabilization of p53. In this regard,
MDM2 is an essential negative regulator of p53 [49].
MDM2 is an E3 ubiquitin ligase that promotes the rapid
and continuous degradation of p53 and modulates p53
localization, stability, and transcriptional activity [49].
We recently found that MDM2-p53 pathway is involved
in PC-promoted neuronal ischemic tolerance in both
in vitro and in vivo models [30]. More specifically, we
have demonstrated that NMDA-PC increases neuronal
MDM2 protein levels, thus preventing ischemia-induced
p53 stabilization and promoting neuroprotection [30].
Here, we found that neurons subjected to ischemia prior
NMDA-PC express high levels of MDM2 in both
Arg72Pro genotypes. However, the combination of
NMDA-PC+OGD prevented the aforement ioned
stabilization of p53 only in Pro72-p53 neurons indicating
that only preconditioned Pro72-p53 neurons might display
p53 destabilization and increased protection against ische-
mia through a MDM2-dependent mechanism. In fact, nu-
clear accumulation of Pro72-p53 variant might be deci-
sive to MDM2-mediated translocation of p53 from nucle-
us to cytosol and subsequent degradation by proteasome,
which might be responsible for differences between
genotypes.
In response to ischemia, a fraction of stabilized p53 trans-
locates to mitochondria leading a rapid pro-apoptotic response
in a transcriptional-independent manner [50, 51]. In particular,
the mitochondrial accumulation observed in Arg72-p53, but
not Pro72-p53 variant, promotes cytochrome c release and
caspase 9 activation after ischemia in neurons [22]. Here, we
observed that p53 stabilization in mitochondria is not
prevented byNMDA-PC inArg72-p53 neurons, whichmakes
them more vulnerable to ischemia-induced mitochondrial
membrane disruption and subsequent apoptotic death with
respect to Pro72-p53 ones. This might explain the beneficial
neuroprotective effects of NMDA-PC exclusively observed in
Pro72-p53 neurons.
The p53 protein controls the cell survival/death decision by
inducing apoptosis-related genes, such as PUMA, or promot-
ing caspase activation [21]. Several studies have demonstrated
that the absence of p53 and caspase-3 protects neurons against
ischemic insult [52]. Here, we show that NMDA-PC prevents
ischemia-induced apoptosis and caspase-3 activation in
Pro72-p53 neurons, but fails to protect Arg72-p53 cortical
neurons against ischemia. Our data are therefore consistent
with the idea that the human Tp53 Arg72Pro SNP modulates
NMDA-PC-promoted neuroprotection against ischemia by
controlling the p53 mitochondrial translocation and later
p53/caspase-3 pathway.
Transient ischemic attack (TIA) before ischemic stroke
could represent a clinical equivalent of cerebral PC [4, 5].
TIAs are temporary episodes associated with relative be-
nign short-term consequences, but they can be a warning
signal of an impending stroke. Hence, the relevance of
finding an appropriate marker to predict the functional
prognosis of patients suffering from TIA might help to act
accordingly in case of later stroke. In good agreement with
several clinical results [9, 10], we confirmed the neuropro-
tective role of TIA within first month before an ischemic
stroke. Although shorter times between TIA and subse-
quent stroke could provide better protection, our results
showed that 1-month-time interval is also capable to pro-
mote this beneficial effect in patients. However, we dem-
onstrated that TIA is not sufficient to ensure better progno-
sis of patients, but human Tp53 Arg72Pro SNP can modu-
late their evolution. Even though TIA influenced the func-
tional outcome of preconditioned patients, Arg/Arg geno-
type associated with poor prognosis after ischemia
Table 1 Baseline demographic and clinical features of patients. TIA,
transient ischemic attack; NIHSS, National Institute of Health Stroke
Scale; SNP, single-nucleotide polymorphism. Patients were admitted at
the University Hospital of Salamanca and Valladolid and the University
Hospital Arnau de Vilanova, Lleida (Spain). Data are shown as
percentage (n, %), mean (S. D.) or medians (quartiles)
TIA (N = 25) No TIA (N = 60)
Age (years) 71.20(±13.1) 72.64(±13.1)
Gender
Males, n (%) 14 (56) 33 (55)
Females, n (%) 11 (44) 27 (45)
Previous
Hypertension, n (%) 16 (64) 40 (66.6)
Diabetes, n (%) 8 (32) 17 (28.3)
Smoking, n (%) 7 (28) 8 (13.3)
Hyperlipidemia, n (%) 12 (48) 23 (38.3)
Atrial fibrillation, n (%) 4 (16) 14 (23.3)
NIHSS on admission
Minor stroke, n (%) 12 (48) 21 (35)
Moderate stroke, n (%) 11 (44) 26 (43)
Moderate to severe stroke, n (%) 0 12 (20)
Severe stroke, n (%) 2 (8) 1 (1.6)
TOAST
Cardioembolic, n (%) 7 (28) 17 (28)
Atherothrombotic, n (%) 5 (20) 13 (21.6)
Lacunar, n (%) 2 (8) 7 (11,6)
Undetermined, n (%) 4 (16) 26 (43.3)
Others, n (%) 2 (8) 2 (3.3)
Tp53 Arg72Pro
Arg (Arg/Arg), n (%) 12 (48) 33 (55)
Pro (Arg/Pro and Pro/Pro), n (%) 13 (52) 27 (45)
Transl. Stroke Res.
compared to Pro allele-carrying subjects. The Pro72-p53
variant has been already described as a genetic marker
predicting functional outcome after ischemic or hemor-
rhagic stroke [22]. Here, the benefit associated with Pro
patients suffering TIA within first month prior stroke was
shown. Taken together, our results indicate that TIA dis-
plays a more efficient protective mechanism against poor
functional outcome in Pro patients suffering stroke than in
Arg patients.
In conclusion, our findings demonstrate that Tp53
Arg72Pro polymorphism modulates NMDA-PC-induced
neuroprotection against a subsequent ischemic insult,
through a mechanism that involves p53 stabilization and
modulation of ischemia-induced apoptosis. The clinical rel-
evance of the human Tp53 Arg72Pro polymorphism in
TIA-promoted neuroprotection and its role in ischemic tol-
erance are also stablished in patients. Accordingly, the hu-
man Tp53 Arg72Pro polymorphism might be considered as
a noninvasive molecular biomarker to predict the
functional prognosis and ischemic tolerance in patients
who have experienced a TIA.
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Fig. 4 TIA associates with a
better prognosis in stroke patients
with Pro72-p53 genotype.
Eighty-five patients were
admitted at the University
Hospital of Valladolid, University
Hospital of Salamanca and
University Hospital Arnau
Vilanova of Lleida (Spain). The
study included (a) 25 TIA
patients, (b) Arg/Pro andPro/Pro:
13, referred as Pro and (c) Arg/
Arg: 12, referred as Arg patients,
with TIAwithin 1 month before
stroke and 27 (Pro) and 13 Arg)
without TIA, respectively.
Modified Rankin Scale (mRS)
was used to evaluate the
functional outcome of TIA or No
TIA patients prior ischemia. mRS
score at 3 months after ischemia
with indicated Tp53 Arg72Pro
genotypes (b, c) or not (a).
Fisher’s test *p < 0.0001 versus
No TIA patients
Table 2 Functional outcome of stroke patients with previous TIA.
Patients were matched by good (mRS ≤ 2) and poor (mRS > 2)
prognosis at 3 months after stroke with indicated Tp53 Arg72Pro
genotypes
Good prognosis Poor prognosis p
Pro, n (%) 13 (100%) 0 0.04
Arg, n (%) 8 (67%) 4 (33%)
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